TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02700711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
Study: NCT04610463

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac flow measurement
Description: Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
Study: NCT01295866

Intervention type: DEVICE
Intervention: nasal nitric oxide
Study: NCT04129320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enoblituzumab
Description: anti-B7-H3 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enoblituzumab
Description: anti-B7-H3 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA012
Description: anti-PD-1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD013
Description: PD-1 X LAG-3 bispecific DART protein
Study: NCT00999648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point pressure release (deactivation)
Description: The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo myofascial trigger point pressure release
Description: The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
Study: NCT01684137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Joalis Bambi Analerg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Joalis Bambi Bronchi

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Joalis Bambi Analerg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Joalis Bambi Bronchi
Study: NCT01790035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02212912

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement intervention
Description: Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters.
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01961193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contact lens
Description: A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctal plug
Description: A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
Study: NCT00565045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulator
Description: Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulator
Description: Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible).
Study: NCT03193203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg/mL PFS and AI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg/mL PFS and AI
Study: NCT03039140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend weekly educational sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in CR program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03606499

Intervention type: DRUG
Intervention: Ustekinumab
Description: No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
Study: NCT02803632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphic recording
Study: NCT03384238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging
Study: NCT02709850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9%NaCl, water, riboflavin
Study: NCT02212912

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no intervention
Description: No intervention indicated that the physicians among control hospital provide routine
Study: NCT04385966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999).
Study: NCT05417503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation bi-level
Description: For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-invasive ventilation placebo
Description: The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
Study: NCT03384238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging
Study: NCT00700609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family therapy (ABFT)
Description: Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attachment Based Family therapy (ABFT)
Description: Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
Study: NCT01377675

Intervention type: OTHER
Intervention: Education
Description: The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
Study: NCT03126916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03073395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P16-093
Description: Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P16-093
Description: Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
Study: NCT02123212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailer
Description: Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person recruitment
Description: UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Alert
Description: EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
Study: NCT01986010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Low Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Low Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection
Study: NCT00212134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens correction of aphakia
Description: optical correction of infant surgical aphakia with Contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens implantation
Description: optical correction of surgical aphakia with intraocular lens
Study: NCT01986010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
Description: V160 plus MAPA administered as a 0.75 mL intramuscular injection
Study: NCT03126916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study: NCT01058499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program (MBSR)
Description: Traditional eight-week MBSR Program.
Study: NCT04313205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-122 in capsule or tablet form
Description: JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-122 in capsule or tablet form
Description: JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
Study: NCT01109524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
Study: NCT00003612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT03126916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT00003612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel